The planned mandate of the US National Institutes of Health (NIH) to include both sexes in effectively all preclinical studies could undermine its own objective by wasting resources, slowing down research or even provoking a backlash (see J. A. Clayton and F. S. Collins Nature 509, 282-283; 2014) . Instead of a blanket mandate, the NIH should be promoting research into the sex differences that are important to science and in disease.
Duplicating studies to "compare and contrast experimental findings in male and female animals and cells" is rarely practical, affordable, prudent, scientifically warranted or ethically justifiable. Researchers use both sexes because this roughly halves the costs of breeding and maintenance. Sometimes one sex is excluded if results are likely to differ between sexes, and possibly for well-known reasons -for instance, male rats run faster than female rats through a maze. If there is no justification for studying both sexes, then it should not be done.
Clayton and Collins suggest that statistical variability will not be increased by using equal numbers of male and female cells or animals in studies, but this is questionable and undermines the premise for the NIH's argument. If the sexes were not different, there would be no need to use both. Variances are additive, so using both sexes halves sample size while increasing variance, making it less likely that an observed difference not due to sex can be detected at a statistically significant level. Thus, an increased number of samples would be needed to reach firm conclusions.
Understanding gender differences in disease is a goal in itself, but this will not be attained as a by-product of mandating its intrusion into every hypothesis under investigation.
NIH policy: status quo is also costly
Researchers have raised concerns about the cost of requiring applicants for US National Institutes of Health (NIH) grants to use male and female animals or cells in preclinical research (see J. A. Clayton and F. S. Collins Nature 509, 282-283; 2014) . But they should also consider the costs of not taking sex into account: these include failed clinical trials, misdiagnosis and inappropriate therapies for women, and omission of fundamental biological principles.
Many researchers are still unfamiliar with the distinction between sex and gender. Gender combines self-and societal perceptions of a person's sex, so applies only to humans. Sex is the biological result of interplay between sex chromosomes and gonadal hormones.
The impact of sex is dynamic, changing throughout lifespan and in response to injury and disease. Ruling out the influence of sex on a particular endpoint will sometimes be as difficult as identifying it. Sex must be evaluated in the context of other variables, such as age, experience, genetics and environment.
Age-appropriate medicine is a well-accepted idea that is reflected in the formation of NIH centres studying ageing and child health. 485-488; 2012) . Code is a valuable part of a paper, so everyone benefits if its authors assume from the start that it will be shared or reused. Also, people releasing code are under no obligation to maintain it. Stephen Eglen University of Cambridge, UK. sje30@cam.ac.uk 
